A-SEEDS Co., Ltd.
As of April 2024
| City | Year of Establishment | Founder |
|---|---|---|
| Matsumoto, Nagano | 2020 | Yozo Nakazawa |
| Partner VC | Latest round of Fundraising | Valuation |
|---|---|---|
| - | Seed Round | Non-Disclosure |
- Contact Information : 0263-31-5882
- kiyohito.tani@a-seeds.co.jp
- Website :
A-SEEDS Co., Ltd.
Program name
Deep-Tech Startups Support Program
Research theme
Development of Mass-Production Technology for the Clinical Implementation of Innovative CAR-T Cell Therapy
Business Plan
A-SEEDS, an innovative biotech company sprouted from Shinshu University, is dedicated to pioneering advanced treatments for life-threatening cancers. Harnessing the potential of non-viral genetic engineering, our cutting-edge immune cell therapy opens up new horizons of hope for patients seeking effective and transformative solutions.
Research Outline
The objective of this project is to develop mass-production technology for CAR-T cell therapy, a novel approach to cancer treatment, utilizing non-viral gene editing methods. Our focus extends to establishing a manufacturing base in collaboration with pharmaceutical formulation development and manufacturing support companies, both domestically and globally. This foundation will support the conduct of international clinical trials and the pursuit of regulatory approvals.
| Phase | Business Area/Field | Research Period | Research Grant Amount |
|---|---|---|---|
| PCA | Healthcare | 2024～2025FY | JPY 79 million |
Download this pageLast Updated : June 6, 2024